209 related articles for article (PubMed ID: 18423560)
1. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia.
Nimeiri HS; Oza AM; Morgan RJ; Friberg G; Kasza K; Faoro L; Salgia R; Stadler WM; Vokes EE; Fleming GF; ; ;
Gynecol Oncol; 2008 Jul; 110(1):49-55. PubMed ID: 18423560
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of bevacizumab and pemetrexed for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer.
Hagemann AR; Novetsky AP; Zighelboim I; Gao F; Massad LS; Thaker PH; Powell MA; Mutch DG; Wright JD
Gynecol Oncol; 2013 Dec; 131(3):535-40. PubMed ID: 24096113
[TBL] [Abstract][Full Text] [Related]
3. What is the benefit of bevacizumab combined with chemotherapy in patients with recurrent ovarian, fallopian tube or primary peritoneal malignancies?
Cheng X; Moroney JW; Levenback CF; Fu S; Jaishuen A; Kavanagh JJ
J Chemother; 2009 Nov; 21(5):566-72. PubMed ID: 19933049
[TBL] [Abstract][Full Text] [Related]
4. A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer.
del Carmen MG; Micha J; Small L; Street DG; Londhe A; McGowan T
Gynecol Oncol; 2012 Sep; 126(3):369-74. PubMed ID: 22659190
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
Herzog TJ; Monk BJ; Rose PG; Braly P; Hines JF; Bell MC; Wenham RM; Secord AA; Roman LD; Einstein MH; Drake RD; Childs BH
Gynecol Oncol; 2014 Mar; 132(3):517-25. PubMed ID: 24476788
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia.
Garcia AA; Hirte H; Fleming G; Yang D; Tsao-Wei DD; Roman L; Groshen S; Swenson S; Markland F; Gandara D; Scudder S; Morgan R; Chen H; Lenz HJ; Oza AM
J Clin Oncol; 2008 Jan; 26(1):76-82. PubMed ID: 18165643
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
Taylor SE; Chu T; Elvin JA; Edwards RP; Zorn KK
Gynecol Oncol; 2020 Jan; 156(1):32-37. PubMed ID: 31739991
[TBL] [Abstract][Full Text] [Related]
8. Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
Monk BJ; Sill MW; Walker JL; Darus CJ; Sutton G; Tewari KS; Martin LP; Schilder JM; Coleman RL; Balkissoon J; Aghajanian C
J Clin Oncol; 2016 Jul; 34(19):2279-86. PubMed ID: 27217446
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma.
Penson RT; Moore KM; Fleming GF; Braly P; Schimp V; Nguyen H; Matulonis UA; Banerjee S; Haluska P; Gore M; Bodurka DC; Hozak RR; Joshi A; Xu Y; Schwartz JD; McGuire WP
Gynecol Oncol; 2014 Sep; 134(3):478-85. PubMed ID: 25016924
[TBL] [Abstract][Full Text] [Related]
10. A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer.
Nanki Y; Nomura H; Iwasa N; Saotome K; Dozen A; Yoshihama T; Hirano T; Hashimoto S; Chiyoda T; Yamagami W; Kataoka F; Aoki D
Jpn J Clin Oncol; 2021 Jan; 51(1):54-59. PubMed ID: 32776094
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Nagao S; Kogiku A; Suzuki K; Shibutani T; Yamamoto K; Jimi T; Kitai M; Shiozaki T; Matsuoka K; Yamaguchi S
J Ovarian Res; 2020 Feb; 13(1):14. PubMed ID: 32028974
[TBL] [Abstract][Full Text] [Related]
12. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer.
Coleman RL; Duska LR; Ramirez PT; Heymach JV; Kamat AA; Modesitt SC; Schmeler KM; Iyer RB; Garcia ME; Miller DL; Jackson EF; Ng CS; Kundra V; Jaffe R; Sood AK
Lancet Oncol; 2011 Nov; 12(12):1109-17. PubMed ID: 21992853
[TBL] [Abstract][Full Text] [Related]
13. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Matulonis UA; Berlin S; Ivy P; Tyburski K; Krasner C; Zarwan C; Berkenblit A; Campos S; Horowitz N; Cannistra SA; Lee H; Lee J; Roche M; Hill M; Whalen C; Sullivan L; Tran C; Humphreys BD; Penson RT
J Clin Oncol; 2009 Nov; 27(33):5601-6. PubMed ID: 19826113
[TBL] [Abstract][Full Text] [Related]
14. An open-label, randomized, phase II trial evaluating the efficacy and safety of standard of care with or without bevacizumab in platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer patients previously treated with bevacizumab for front-line or platinum-sensitive ovarian cancer: rationale, design, and methods of the Japanese Gynecologic Oncology Group study JGOG3023.
Shoji T; Komiyama S; Kigawa J; Tanabe H; Kato K; Itamochi H; Fujiwara H; Kamiura S; Hamano T; Sugiyama T;
BMC Cancer; 2018 Jul; 18(1):771. PubMed ID: 30064406
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Dhillon S
BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
[TBL] [Abstract][Full Text] [Related]
16. Weekly ixabepilone with or without biweekly bevacizumab in the treatment of recurrent or persistent uterine and ovarian/primary peritoneal/fallopian tube cancers: A retrospective review.
Roque DM; Ratner ES; Silasi DA; Azodi M; Rutherford TJ; Schwartz PE; Nelson WK; Santin AD
Gynecol Oncol; 2015 Jun; 137(3):392-400. PubMed ID: 25792179
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer.
Chambers SK; Clouser MC; Baker AF; Roe DJ; Cui H; Brewer MA; Hatch KD; Gordon MS; Janicek MF; Isaacs JD; Gordon AN; Nagle RB; Wright HM; Cohen JL; Alberts DS
Clin Cancer Res; 2010 Nov; 16(21):5320-8. PubMed ID: 21041183
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy.
Wenham RM; Lapolla J; Lin HY; Apte SM; Lancaster JM; Judson PL; Gonzalez-Bosquet J; Herschberger A; Havrilesky LJ; Secord AA
Gynecol Oncol; 2013 Jul; 130(1):19-24. PubMed ID: 23623830
[TBL] [Abstract][Full Text] [Related]
19. A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
Hall MR; Dehbi HM; Banerjee S; Lord R; Clamp A; Ledermann JA; Nicum S; Lilleywhite R; Bowen R; Michael A; Feeney A; Glasspool R; Hackshaw A; Rustin G
Gynecol Oncol; 2020 Dec; 159(3):692-698. PubMed ID: 33077258
[TBL] [Abstract][Full Text] [Related]
20. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and fallopian tube cancer.
Micha JP; Goldstein BH; Rettenmaier MA; Genesen M; Graham C; Bader K; Lopez KL; Nickle M; Brown JV
Int J Gynecol Cancer; 2007; 17(4):771-6. PubMed ID: 17343605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
